Il Dong Pharmaceutical Co Ltd (249420) - Total Liabilities

Latest as of September 2025: ₩347.04 Billion KRW ≈ $235.18 Million USD

Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has total liabilities worth ₩347.04 Billion KRW (≈ $235.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Il Dong Pharmaceutical Co Ltd (249420) equity growth momentum to track the company's year-over-year net asset growth rate.

Il Dong Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Il Dong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 249420 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Il Dong Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Galata Wind Enerji Anonim Sirket
IS:GWIND
Turkey TL6.55 Billion
Shanxi C&Y Pharmaceutical Group Co Ltd
SHE:300254
China CN¥1.07 Billion
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
Turkey TL1.56 Billion
Bleichroeder Acquisition Corp. II Class A Ordinary Shares
NASDAQ:BBCQ
USA $16.75 Million
Hypothekarbank Lenzburg AG
SW:HBLN
Switzerland CHF7.55 Billion
Zhengzhou J and T Hi Tech Co
SHE:300845
China CN¥195.24 Million
SolGold PLC
TO:SOLG
Canada CA$242.89 Million
Jiusheng Electric Co. LTD
SHE:301082
China CN¥2.74 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Il Dong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Il Dong Pharmaceutical Co Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.50 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.60 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Il Dong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Il Dong Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual total liabilities of Il Dong Pharmaceutical Co Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 ₩429.99 Billion
≈ $291.39 Million
-1.60%
2023-12-31 ₩437.00 Billion
≈ $296.15 Million
-4.50%
2022-12-31 ₩457.59 Billion
≈ $310.10 Million
-16.56%
2021-12-31 ₩548.39 Billion
≈ $371.63 Million
+56.36%
2020-12-31 ₩350.73 Billion
≈ $237.68 Million
-2.53%
2019-12-31 ₩359.83 Billion
≈ $243.85 Million
+25.01%
2018-12-31 ₩287.84 Billion
≈ $195.07 Million
+2.97%
2017-12-31 ₩279.55 Billion
≈ $189.45 Million
-0.85%
2016-12-31 ₩281.94 Billion
≈ $191.07 Million
--

About Il Dong Pharmaceutical Co Ltd

KO:249420 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$293.17 Million
₩432.61 Billion KRW
Market Cap Rank
#14813 Global
#458 in Korea
Share Price
₩13730.00
Change (1 day)
+9.05%
52-Week Range
₩12150.00 - ₩44300.00
All Time High
₩75500.00
About

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more